Accessibility Statement

We are committed to providing a website that is accessible to the widest possible audience. To do so, we are actively working with consultants to update the website by increasing its accessibility and usability by persons who use assistive technologies such as automated tools, keyboard-only navigation, and screen readers.

We are working to have the website conform to the relevant standards of the Section 508 Web Accessibility Standards developed by the United States Access Board, as well as the World Wide Web Consortium's (W3C) Web Content Accessibility Guidelines 2.1. These standards and guidelines explain how to make web content more accessible for people with disabilities. We believe that conformance with these standards and guidelines will help make the website more user friendly for all people.

Our efforts are ongoing. While we strive to have the website adhere to these guidelines and standards, it is not always possible to do so in all areas of the website. If, at any time, you have specific questions or concerns about the accessibility of any particular webpage, please contact WebsiteAccess@tenethealth.com so that we may be of assistance.

Thank you. We hope you enjoy using our website.

Skip to Main Content

FMC First in Florida to Offer High Sensitive STAT Blood Test for Diagnosis of Heart Attacks

Mar 3, 2020

Lauderhill Lakes, August 30, 2017– The Heart Institute at Florida Medical Center, a campus of North Shore  is the first hospital in the state of Florida to offer the recently FDA-cleared high sensitive Elecsys Troponin T Gen 5 blood test (Troponin T Gen 5 or TnT Gen 5) to aid in the diagnosis of heart attacks.  The new 9-minute test offers faster answers clinicians can use when diagnosing heart attack.

“This next-generation Troponin T assay from Roche Diagnostics allows clinicians to make better choices when identifying heart attack and thereby enhances our diagnostic abilities for our patients, especially as we use the gender-specific cutoffs,” says Dr. Louis Isaacson, director of emergency services at Florida Medical Center. “Using the TnT Gen 5 test, we can rule in or rule out cardiac disease; in particular, acute myocardial infarction.”

Every 43 seconds someone in the U.S. has a heart attack, or acute myocardial infarction (AMI), which occurs when the blood supply to an area of the heart is interrupted. The longer the heart is without proper blood supply, the greater the damage. Troponin, a specific marker of cardiac cell death, is released into the blood stream when cardiac cells are being damaged. By detecting small elevations of troponin, the highly sensitive Troponin T Gen 5 test aids in the diagnosis of a heart attack and can help save lives.

“Patients with chest pain and other symptoms suggestive of AMI account for approximately 8 million of all emergency room consultations in the U.S.,” explains Roche Chief Medical Officer Alan Wright, “but only a fraction of them—5-20 percent—are actually having an AMI. Helping fast, accurate diagnosis using TnT Gen 5 allows healthcare providers to make confident decisions and provide better care.”

Using the hsTnT (TnT Gen 5) test, in combination with an electrocardiogram (ECG) and clinical signs of inadequate blood supply, allows emergency department physicians to stratify patients according to risk in order to determine the best care plan for individual patients.

“Our goal is to be able to send more patients home for outpatient cardiology follow-up rather than have them deal with an unnecessary hospitalization, says Trey Abshier, CEO of Florida Medical Center. “We want to focus on continuing to set the standard for the diagnosis and treatment of acute cardiac problems in the state in order to better serve the patients who entrust us with their care.”

Find a Doctor

Need a doctor for your care? 

Sign Up for Health Tips

Get our advice and upcoming events about weight, pain, heart and more.